160 related articles for article (PubMed ID: 12800342)
1. GDPs and AGEs: local and systemic effects in PD patients.
Ledebo I; Wieslander A; Deppisch R
Contrib Nephrol; 2003; (140):38-46. PubMed ID: 12800342
[No Abstract] [Full Text] [Related]
2. Long-term results with low glucose degradation product content in peritoneal dialysis fluids.
Rippe B; Wieslander A; Musi B
Contrib Nephrol; 2003; (140):47-55. PubMed ID: 12800343
[No Abstract] [Full Text] [Related]
3. Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system.
Passlick-Deetjen J; Lage C
Perit Dial Int; 2000; 20 Suppl 2():S42-7. PubMed ID: 10911642
[No Abstract] [Full Text] [Related]
4. Re: effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: a 3-year follow-up study.
Ahmadi F
Iran J Kidney Dis; 2014 Mar; 8(2):158-60. PubMed ID: 24685741
[No Abstract] [Full Text] [Related]
5. Strategy for preventing peritoneal dialysis failure.
Cancarini G
Contrib Nephrol; 2001; (131):114-24. PubMed ID: 11125557
[No Abstract] [Full Text] [Related]
6. A peritoneal dialysis solution prepared from a three-compartment bag: biological and clinical effects.
Cappelli G; Amore A; Bandiani G; Cancarini G; Coppo R; Feriani M; Dell'Aquila R; Saffioti S; Spisni C; Stingone A; Orazi E; Ballocchi S; Renaux JL
Contrib Nephrol; 2001; (131):97-106. PubMed ID: 11125568
[No Abstract] [Full Text] [Related]
7. Glucose degradation products and peritoneal membrane function.
Witowski J; Bender TO; Gahl GM; Frei U; Jörres A
Perit Dial Int; 2001; 21(2):201-5. PubMed ID: 11330569
[TBL] [Abstract][Full Text] [Related]
8. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal transport in long-term peritoneal dialysis patients and its relation with AGEs.
Feriani M
Contrib Nephrol; 2001; (131):74-81. PubMed ID: 11125565
[No Abstract] [Full Text] [Related]
10. Unfavorable Effects of Peritoneal Dialysis Solutions on the Peritoneal Membrane: The Role of Oxidative Stress.
Roumeliotis S; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
Biomolecules; 2020 May; 10(5):. PubMed ID: 32423139
[TBL] [Abstract][Full Text] [Related]
11. In vitro superiority of dual-chambered peritoneal dialysis solution with possible clinical benefits.
Passlick-Deetjen J; Pischetsrieder M; Witowski J; Bender TO; Jörres A; Lage C
Perit Dial Int; 2001; 21 Suppl 3():S96-101. PubMed ID: 11887872
[No Abstract] [Full Text] [Related]
12. Glucose degradation products and the peritoneal mesothelium.
Jörres A; Bender TO; Witowski J
Perit Dial Int; 2000; 20 Suppl 5():S19-22. PubMed ID: 11229607
[TBL] [Abstract][Full Text] [Related]
13. Glutathione depletion as a mechanism of 3,4-dideoxyglucosone-3-ene-induced cytotoxicity in human peritoneal mesothelial cells: role in biocompatibility of peritoneal dialysis fluids.
Yamamoto T; Tomo T; Okabe E; Namoto S; Suzuki K; Hirao Y
Nephrol Dial Transplant; 2009 May; 24(5):1436-42. PubMed ID: 19033251
[TBL] [Abstract][Full Text] [Related]
14. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients.
Do JY; Kim YL; Park JW; Cho KH; Kim TW; Yoon KW; Kim CD; Park SH; Han JH; Song IH
Perit Dial Int; 2005 Feb; 25 Suppl 3():S22-5. PubMed ID: 16048250
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal microcirculation.
Lameire N; Mortier S; De Vriese A
Contrib Nephrol; 2003; (140):56-69. PubMed ID: 12800344
[No Abstract] [Full Text] [Related]
16. Solution formulation for continuous flow peritoneal dialysis.
Diaz-Buxo JA
Contrib Nephrol; 2003; (140):309-17. PubMed ID: 12800373
[No Abstract] [Full Text] [Related]
17. APD schedules and clinical results.
Durand PY
Contrib Nephrol; 2003; (140):272-7. PubMed ID: 12800369
[No Abstract] [Full Text] [Related]
18. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.
Kawanishi K; Honda K; Tsukada M; Oda H; Nitta K
Perit Dial Int; 2013; 33(3):242-51. PubMed ID: 23123670
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration on peritoneum: a case report.
Shimizu H; Ishibashi Y; Kumagai T; Kaname S; Fujita T; Sai K; Nishi T; Mise N; Tagawa H; Sugimoto T
Perit Dial Int; 2007; 27(1):92-4. PubMed ID: 17179519
[No Abstract] [Full Text] [Related]
20. AGE accumulation in peritoneal membrane and cavity during peritoneal dialysis and its effect on peritoneal structure and function.
Park MS; Lee HB
Perit Dial Int; 1999; 19 Suppl 2():S53-7. PubMed ID: 10406494
[No Abstract] [Full Text] [Related]
[Next] [New Search]
